Evidence map›Paper›PMID 31218580›Full record

SynthesisThe European journal of health economics : HEPAC : health economics in prevention and care2019

Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic review.

Antonio Ahumada-Canale, Camila Quirland, Francisco J Martinez-Mardones, José Cristian Plaza-Plaza, Shalom Benrimoj, Victoria Garcia-Cardenas

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The European journal of health economics : HEPAC : health economics in prevention and care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Antonio Ahumada-CanaleGraduate School of Health, University of Technology Sydney, Broadway, PO Box 123, Sydney, NSW, 2007, Australia. Antonio.o.ahumadacanale@student.uts.edu.au.ORCID http://orcid.org/0000-0001-6806-1422
Camila QuirlandOncology Institute, Arturo López Pérez Foundation, Santiago, Chile.ORCID http://orcid.org/0000-0002-0799-3303
Francisco J Martinez-MardonesGraduate School of Health, University of Technology Sydney, Broadway, PO Box 123, Sydney, NSW, 2007, Australia.ORCID http://orcid.org/0000-0002-7721-1813
José Cristian Plaza-PlazaFacultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
Shalom BenrimojEmeritus Professor University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-9768-7838
Victoria Garcia-CardenasGraduate School of Health, University of Technology Sydney, Broadway, PO Box 123, Sydney, NSW, 2007, Australia.ORCID http://orcid.org/0000-0003-3770-4557
University of Technology Sydney · AUFundación Arturo López Pérez · CLPontificia Universidad Católica de Chile · CLThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the health economics evidence based on randomized controlled trials of pharmacist-led medication review in pharmacotherapy managed cardiovascular disease risk factors, specifically, hypertension, type-2 diabetes mellitus and dyslipidaemia in ambulatory settings and to provide recommendations for future evaluations.

methodsA systematic review was carried out according to the Cochrane Handbook for Systematic Reviews. PubMed (Medline), Scopus, Web of Science, National Health System Economic Evaluation Database (NHS EED), Cochrane Library, and Econlit were searched and screened by two independent authors. Incremental cost-effectiveness ratio was the main outcome. Risk of bias was assessed with the Effective Practice and Organisation of Care tool by the Cochrane Collaboration. Economic evaluation quality was assessed with the he Consensus Health Economic Criteria list (CHEC list).

results5636 records were found, and 174 were retrieved for full-text review yielding 11 articles. Eight articles deemed the intervention as cost effective and two as dominant. Two cost-utility analyses were performed yielding ICERs of $612.7 and $59.8 per QALY. Four articles were considered to perform a high-quality economic evaluation and four had a low risk of bias. Future economic evaluations should consider cost-utility analysis, to describe usual care thoroughly, and use time horizons that capture the effect of cardiovascular disease prevention, a societal perspective and uncertainty analysis.

conclusionPharmacist-led medication review has proven to be cost effective in various studies in different settings. Policy decision makers are advised to undertake local economic evaluations reflecting the gaps observed in this systematic review and published literature. If this is not possible, a transferability assessment should be conducted.

Indexed as

Fees, PharmaceuticalOutpatientsPharmacistsDiabetes Mellitus, Type 2DyslipidemiasFemaleHumansHypertensionMaleMedication ReconciliationCardiovascular diseaseEconomic evaluationHypertensionMedication reviewPharmacistType 2 diabetes mellitus

Identifiers

PMID31218580
OpenAlexW2952317397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.